1.Surgical Treatment of Tuberculous Cold Abscess of the Chest Wall.
Hyo Chae PAIK ; Kyung Young CHUNG ; Jeong Han KANG ; Dae Hyeon MAENG
Yonsei Medical Journal 2002;43(3):309-314
The incidence of tuberculosis (Tbc) infection is high in some parts of the world and tuberculous cold abscess of the chest wall (CACW) often fails to respond to medical treatment. Medical records of 178 patients who underwent surgical treatment of chest wall abscesses from July 1970 to Sept. 2000 were reviewed and 89 patients who were pathologically confirmed as Tbc cold abscess cases were included in this study. Their ages ranged from 9 to 71 years (mean 33.3 years) and the male to female ratio was 1.2:1 (49 male, 40 female). The symptoms were palpable chest wall mass, pain and pus discharge, and three patients had multiple lesions. Twenty-five patients (28%) underwent excision of chest wall abscesses and 64 patients (72%) underwent chest wall and rib resection. Tbc medication was given preoperatively in 39 patients for an average of 6.3 months and all patients were given Tbc medication postoperatively for an average of 12 months. Postoperative complications were bleeding, pus discharge, empyema, pleural effusion, wound dehiscence, subcutaneous emphysema and activation of pulmonary Tbc. The disease recurred in 7 patients (7.8%) and these 7 patients all underwent a second operation. We recommend preoperative Tbc medication and complete resection of chest wall abscesses including any suspicious ribs. Postoperative Tbc medication for a minimum of 12 months is essential to decrease the risk of a relapse.
Abscess/drug therapy/*surgery
;
Adolescent
;
Adult
;
Aged
;
Antitubercular Agents/therapeutic use
;
Child
;
Female
;
Human
;
Male
;
Middle Age
;
Retrospective Studies
;
Thoracic Diseases/drug therapy/*surgery
;
*Thoracic Surgical Procedures
;
Thoracic Vertebrae/surgery
;
Tuberculosis/drug therapy/*surgery
2.A Case of Surgical Resection in Hepatocellular Carcinoma with Pulmonary Metastasis.
Woo Jin JUNG ; Jae Young JANG ; Jun Seok PARK ; Hee Jeong LEE ; Young Kyu CHO ; Soung Won JEONG ; Sae Hwan LEE ; Sang Gyune KIM ; Sang Woo CHA ; Young Seok KIM ; Young Deok CHO ; Hong Soo KIM ; Boo Sung KIM
Journal of Liver Cancer 2016;16(2):145-150
Hepatocellular carcinoma (HCC) is well known malignancy with poor prognosis, even after resection of the primary tumor. Sorafenib is the first-line treatment in advanced HCC, but the disease control rate of sorafenib is only 43%. Pulmonary metastasectomy in patients with pulmonary metastasis from HCC has been reported to increase long-term survival compared with systemic chemotherapy. Video-assisted thoracic surgery is considered a reliable approach to the diagnosis and treatment of pulmonary diseases with low complication rate. Pulmonary metastasectomy is not universally accepted because of frequent local recurrence, an uncontrollable primary tumor, and frequent multiple pulmonary metastases in HCC, but outcome of pulmonary metastasectomy and adjuvant sorafenib therapy has not been studied. We experienced a patient who had advanced HCC with pulmonary oligometastasis and received surgical resection of the metastatic pulmonary nodule and sorafenib chemotherapy. In advanced HCC with pulmonary oligometastasis, surgical resection of pulmonary metastasis and sorafenib chemotherapy should be considered.
Carcinoma, Hepatocellular*
;
Diagnosis
;
Drug Therapy
;
Humans
;
Lung Diseases
;
Metastasectomy
;
Neoplasm Metastasis*
;
Prognosis
;
Recurrence
;
Thoracic Surgery, Video-Assisted
3.Successful Pulmonary Resection Combined with Chemotherapy for the Treatment of Mycobacterium avium Pulmonary Disease: A Case Report.
Won Jung KOH ; O Jung KWON ; Eun Hae KANG ; Gee Young SUH ; Man Pyo CHUNG ; Hojoong KIM ; Kwhanmien KIM ; Nam Yong LEE ; Joungho HAN ; Tae Sung KIM ; Kyung Soo LEE
Tuberculosis and Respiratory Diseases 2003;54(6):621-627
The Mycobacterium avium complex (MAC) is the most common pathogen causing nontuberculous mycobacterial pulmonary disease. Despite the introduction of newer, more effective agents for the treatment of MAC, such as clarithromycin, the response to drug therapy in MAC pulmonary disease remains poor, and often frustrating. When MAC pulmonary disease has not been successfully eradicated using drug treatment alone, surgical management is still recognized to play a significant role. A case of MAC pulmonary disease, in a patient whose MAC disease was successfully treated by pulmonary resection, following the failure of drug therapy containing clarithromycin, is reported. To our knowledge, this is the first case report in Korea that the patient underwent a pulmonary resection for the treatment of MAC pulmonary disease.
Clarithromycin
;
Drug Therapy*
;
Humans
;
Korea
;
Lung Diseases*
;
Mycobacterium avium Complex
;
Mycobacterium avium*
;
Mycobacterium*
;
Nontuberculous Mycobacteria
;
Thoracic Surgery
4.A Rare Radiological Presentation of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma as Bronchovascular Thickening and Ground Glass Opacities with Concurrent Pancreas Involvement.
Yun Mi KWAK ; Ho Sung LEE ; Ki Hyun SEO ; Ji Won LYU ; Si Hyong JANG ; Ju Ock NA
Soonchunhyang Medical Science 2016;22(2):151-154
Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease and usually presents as pulmonary masses, mass-like consolidation, or pulmonary nodules on chest images. We report a case of a 43-year-old man with symptoms of chronic cough for 1 year, showing bilateral diffuse bronchovascular bundle thickening and focal ground glass opacities on a chest computed tomography scan. Video-assisted thoracoscopic surgery was performed and the final pathologic diagnosis was pulmonary MALT lymphoma. Concurrent involvement of the pancreas was discovered during staging workup. After diagnosis, he was treated with cytotoxic chemotherapy and rituximab and showed improvements in his lung lesion and pancreas.
Adult
;
Cough
;
Diagnosis
;
Drug Therapy
;
Glass*
;
Humans
;
Lung
;
Lymphoid Tissue
;
Lymphoma
;
Lymphoma, B-Cell, Marginal Zone*
;
Pancreas*
;
Rare Diseases
;
Rituximab
;
Thoracic Surgery, Video-Assisted
;
Thorax
5.Successful Treatment of Mycobacterium celatum Pulmonary Disease in an Immunocompetent Patient Using Antimicobacterial Chemotherapy and Combined Pulmonary Resection.
Hee Jung JUN ; Nam Yong LEE ; Jhingook KIM ; Won Jung KOH
Yonsei Medical Journal 2010;51(6):980-983
Mycobacterium celatum is a nontuberculous mycobacterium that rarely causes pulmonary disease in immunocompetent subjects. We describe the successful treatment of M. celatum lung disease with antimicobacterial chemotherapy and combined pulmonary resection. A 33-year-old woman was referred to our hospital with a 3-month history of a productive cough. Her medical history included pulmonary tuberculosis 14 years earlier. Her chest X-ray revealed a large cavitary lesion in the left upper lobe. The sputum smear was positive for acid-fast bacilli, and M. celatum was subsequently identified in more than three sputum cultures, using molecular methods. After 1 year of therapy with clarithromycin, ethambutol, and ciprofloxacin, the patient underwent a pulmonary resection for a persistent cavitary lesion. The patient was considered cured after receiving 12 months of postoperative antimycobacterial chemotherapy. There has been no recurrence of disease for 18 months after treatment completion. In summary, M. celatum is an infrequent cause of potentially treatable pulmonary disease in immunocompetent subjects. Patients with M. celatum pulmonary disease who can tolerate resectional surgery might be considered for surgery, especially in cases of persistent cavitary lesions despite antimycobacterial chemotherapy.
Adult
;
Anti-Infective Agents/*therapeutic use
;
Female
;
Humans
;
Lung/*surgery
;
Lung Diseases/*drug therapy/*microbiology/*surgery
;
Mycobacterium/*metabolism
;
Mycobacterium Infections/*drug therapy
;
Radiography, Thoracic/methods
;
Treatment Outcome
;
Tuberculosis, Pulmonary/complications
6.Analysis of Risk and Benefit of Open Lung Biopsy in Severe Immunocompromised Patients with Pulmonary Complications.
Ho Seok I ; Sung Ho LEE ; Kwhan Mien KIM ; Young Mog SHIM ; Jung Ho HAN ; Kyung Soo LEE ; Jhin Gook KIM
The Korean Journal of Thoracic and Cardiovascular Surgery 2001;34(7):539-546
BACKGROUND: Pulmonary complications in immunocompromised patients are often fatal. Empirical treatment is usually applied based on the clinical and radiological findings because of the risk of the aggressive diagnostic procedures such as open lung biopsy. However, recent advancements in operative procedures and perioperative management has decreased the procedure-related risks. We have prospectively analyzed the risks and benefits of the early application of open lung biopsy in such patients. MATERIAL AND METHOD: Forty-two consecutive immunocompromised patients with critical pulmonary complications were included from June, 1996 to December, 1999. The definition of the immunocompromised is as those with chemotherapy and/or other modality for hematologic disorders, with usage of immunosuppressive drug after transplantation, with usage of steroid for more than 1 month, and with primary immunodeficiency disorders. The indication of open lung biopsy was those with no significant improvement after a week of aggressive application of empirical treatment or with rapidly aggressive process. The underlying disease included hematologic disorder(31 patients), post-transplantation(3 patients), chemotherapy for solid tumor(2 patients), and others(6 patients). Operations were done through thoracotomy(conventional or mini-) or VATS. RESULT: One patient died on the first postoperative day and seven patients died in the hospital after the operation but none was related to the operation. Preoperative usage of steroid and preoperative mechanical ventilator-dependency was significantly related to the in-hospital mortality but the other factors such as thrombocytopenia and neutropenia had no relation to the in-hospital mortality. There was no major or minor surgical complication except for prolonged air leak(1 patient). Postoperative diagnosis included infectious diseases (26 diagnoses; fungal, 20; pyogenic bacteria, 3; mycobacteria, 2; viral, 1), inflammatory disorders(6 diagnoses), malignancy(2 diagnoses), and nonspecifically-defined disorders(13 diagnoses). In 35 patients(81.4%) treatment plans were changed after open lung biopsy and 30 patients(69.8%) improved after change of treatment. CONCLUSION: Open lung biopsy in immunocompromised patients with pulmonary complications can be done with acceptable risk and significant benefit. For accurate diagnosis, adequate treatment, and better prognosis, the early application of open lung biopsy should be considered when the empirical treatment does not improve the patient's condition.
Bacteria
;
Biopsy*
;
Communicable Diseases
;
Diagnosis
;
Drug Therapy
;
Hospital Mortality
;
Humans
;
Immunocompromised Host*
;
Lung Diseases
;
Lung*
;
Neutropenia
;
Prognosis
;
Prospective Studies
;
Risk Assessment
;
Surgical Procedures, Operative
;
Thoracic Surgery, Video-Assisted
;
Thrombocytopenia
7.Reversible Lansoprazole-Induced Interstitial Lung Disease Showing Improvement after Drug Cessation.
Kyu Won HWANG ; Ok Hee WOO ; Hwan Seok YONG ; Bong Kyung SHIN ; Jae Jeong SHIM ; Eun Young KANG
Korean Journal of Radiology 2008;9(2):175-178
Lansoprazole is an acid proton-pump inhibiting drug that is used for the treatment of duodenal or gastric ulcers, H. pylori infection, gastroesophageal reflux disease or Zollinger-Ellison syndrome. Although lansoprazole is well known for its gastrointestinal and dermatologic adverse effects, mild pulmonary symptoms are also known to develop from taking this drug. There have been no reports about lansoprazole-induced interstitial lung disease. We report here a case of lansoprazole-induced interstitial lung disease that developed in a 66-year-old man.
2-Pyridinylmethylsulfinylbenzimidazoles/*adverse effects
;
Aged
;
Anti-Ulcer Agents/*adverse effects
;
Biopsy/methods
;
Gastroesophageal Reflux/drug therapy
;
Humans
;
Lung/*pathology
;
Lung Diseases, Interstitial/*chemically induced
;
Male
;
Thoracic Surgery, Video-Assisted
;
Tomography, X-Ray Computed
8.Acute Fibrinous and Organizing Pneumonia Following Hematopoietic Stem Cell Transplantation.
Sang Min LEE ; Jae Jung PARK ; Sun Hee SUNG ; Yookyung KIM ; Kyoung Eun LEE ; Yeung Chul MUN ; Soon Nam LEE ; Chu Myong SEONG
The Korean Journal of Internal Medicine 2009;24(2):156-159
A 60-year-old man presented with cough, sputum, and dyspnea. He had a history of acute myeloid leukemia and hematopoietic stem cell transplantation with chronic renal failure. Chest CT scans showed miliary nodules and patchy consolidations. Histological examination revealed numerous fibrin balls within the alveoli and thickening of the alveolar septum, both of which are typical pathological features of acute fibrinous and organizing pneumonia (AFOP). We report the first case of AFOP following allogeneic hematopoietic stem cell transplantation.
Acute Disease
;
Anti-Bacterial Agents/therapeutic use
;
Biopsy
;
Cryptogenic Organizing Pneumonia/etiology/pathology
;
Fatal Outcome
;
Glucocorticoids/administration & dosage
;
Hematopoietic Stem Cell Transplantation/*adverse effects
;
Hemoptysis/etiology
;
Humans
;
Leukemia, Myeloid, Acute/*surgery
;
Lung Diseases/*etiology/pathology
;
Male
;
Middle Aged
;
Pleural Effusion/etiology
;
Pulse Therapy, Drug
;
Radiography, Thoracic
;
Respiratory Insufficiency/etiology
;
Tomography, X-Ray Computed